How Mazdutide Achieves Up to 20% Weight Loss in Adults

Obesity remains a growing threat to public health across the globe, especially in Asian countries like India and China. Recently, researchers evaluated the efficacy and safety of once-weekly mazdutide for obesity in Chinese adults. This GLORY-2 randomized clinical trial evaluated a higher 9-mg dose of this dual agonist. Specifically, the drug activates both glucagon-like peptide-1 and glucagon receptors to optimize metabolic outcomes. Consequently, these findings offer a potential breakthrough for long-term weight management in clinical practice.

How Mazdutide for Obesity Promotes Massive Weight Loss

In this phase 3 trial, investigators randomized 461 participants to receive either mazdutide or a placebo. Furthermore, all participants maintained a reduced-calorie diet and increased their physical activity. By week 60, patients using mazdutide achieved an impressive average weight reduction of 16.65%. In contrast, the placebo group experienced only a 1.5% decrease in body weight. Therefore, the active treatment demonstrated a highly significant therapeutic benefit.

Moreover, a remarkably high proportion of participants met the weight-loss targets. Indeed, a vast majority of the mazdutide group achieved at least a 5% weight loss. Importantly, supplementary data indicated that patients without type 2 diabetes achieved even higher reductions, reaching up to 20% weight loss. However, clinicians must note that this efficacy comes with distinct tolerability profiles. Thus, understanding both sides of the drug remains essential for proper patient selection.

Safety Profile and Tolerability of Weekly Mazdutide

Despite the excellent weight-loss efficacy, gastrointestinal side effects were common among patients. Specifically, vomiting occurred in 53.1% of the mazdutide group compared to just 1.3% in the placebo group. Additionally, nausea affected 46.9% of those receiving the active drug versus 3.2% of the placebo group. Fortunately, most of these adverse events were mild to moderate in severity. Consequently, very few participants discontinued the treatment due to these side effects.

Indeed, the dual agonist mechanism represents a major leap forward in metabolic medicine. Because glucagon increases energy expenditure and GLP-1 suppresses appetite, the combination works synergistically. Ultimately, this therapeutic approach could reshape how endocrinologists in India and globally address obesity. Therefore, medical professionals should monitor the clinical progress and upcoming regulatory approvals of this promising medication.

Frequently Asked Questions

Q1: What is mazdutide and how does it work?

Mazdutide is a once-weekly dual agonist that targets both glucagon and glucagon-like peptide-1 (GLP-1) receptors. Consequently, it works by suppressing appetite and increasing energy expenditure simultaneously to achieve robust weight loss.

Q2: What were the key weight loss results from the GLORY-2 trial?

In the GLORY-2 trial, participants on a 9-mg weekly dose of mazdutide achieved a mean weight reduction of 16.65% after 60 weeks. Meanwhile, those in the placebo group experienced only a 1.5% reduction in body weight.

Q3: What are the most common side effects of mazdutide?

Gastrointestinal side effects represent the most common adverse events. Specifically, patients frequently reported vomiting and nausea, though these events were typically mild to moderate in severity.

References

1. Gao L et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026 Jun 07. doi: 10.1001/jama.2026.8142. PMID: 42251595.
2. Innovent Biologics. Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints. PR Newswire. 2025 Nov 19.
3. Innovent Biologics. Press Release: Results of Phase 2 Clinical Study of 9 mg Mazdutide in Chinese Patients with Obesity Published in MED. 2026 Mar 30.